Wettig Thane 4

What Happened
Thane Wettig, CEO and director of Kyntra Bio, received a derivative award on 2026-02-03 covering 60,000 shares at a reported price of $0.00. The filing classifies the grant as an award (code A) and the attached footnote describes the award as an option that vests over time. No cash was paid at grant; this is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-03; Filing date: 2026-02-05 (filed promptly).
• Instrument: Derivative award (listed as an option) for 60,000 shares at $0.00.
• Vesting: Footnote F1 — vests in equal amounts quarterly over 4 years beginning 2/3/2026.
• Shares owned after transaction: Not specified in the excerpt provided (see full Form 4 for post-transaction holdings).
• Filing timeliness: Appears timely (reported within two business days).

Context
This is a time‑based compensation grant designed to retain and incentivize the CEO; it does not represent an immediate purchase or sale of shares. Because the award vests over four years, its economic benefit to the insider depends on future vesting and any exercise terms. For full instrument details (exercise price, settlement type) and holdings after the grant, consult the complete Form 4 filing.